Table 2.
Detailed characteristics of SLE patients included in this study
| No. Patients | Stage | Treatments | Doses (mg/d) | SLEDAI score | Clinical Features |
|---|---|---|---|---|---|
| 1 | inactive | - | - | 4 | PI |
| 2 | inactive | PRD, AZT | 5, 50 | 0 | - |
| 3 | inactive | PRD, AZT | 35, 12.5 | 4 | RA, MU |
| 4 | inactive | PRD, AZT | 5, 25 | 1 | FE |
| 5 | inactive | PRD | N/A | 5 | RA, MU, FE |
| 6 | inactive | PRD | 2.5 | 0 | - |
| 7 | inactive | PRD, CPM | 10, N/A | 4 | PU |
| 8 | inactive | PRD | 5 | 4 | AR |
| 9 | inactive | - | - | 4 | PU |
| 10 | inactive | PRD | 5 | 0 | - |
| 11 | inactive | PRD, AZT | 10, 50 | 4 | PU |
| 12 | inactive | PRD, CPM | 7.5, 25 | 0 | - |
| 13 | inactive | PRD, CPM | 10, 25 | 4 | PU |
| 14 | inactive | PRD | 10 | 2 | MU |
| 15 | inactive | PRD, AZT | 7.5, 100 | 5 | PU, LP |
| 16 | inactive | - | - | 0 | - |
| 17 | active | PRD, AZT | 5, 100 | 8 | HE, PU |
| 18 | active | - | - | 8 | HE, PU |
| 19 | active | PRD, MMF | 2.5, 2,000 | 8 | HE, PU |
| 20 | active | PRD | 15 | 30 | SZ, UC, HE, PU, PI, PE, LC, IDB |
| 21 | active | PRD, AZT | 5, 25 | 11 | MY, HE, PL, LP |
| 22 | active | PRD | 5 | 8 | AR, PU |
| 23 | active | PRD, AZT | 30, 50 | 29 | VA, AR, HE, PU, PI, RA, MU, LP |
| 24 | active | PRD | 30 | 11 | PU, AL, PL, FE, TC, LP |
| 25 | active | PRD, AZT | 5, 50 | 8 | VA |
| 26 | active | PRD, MMF | 5, 500 | 13 | HE, PU, AL, MU, LP |
| 27 | active | PRD | 20 | 12 | HE, PU, PI |
| 28 | active | PRD, AZT | 20, 25 | 16 | VA, PU, MU, LC |
| 29 | active | PRD | 15 | 6 | PU, LC |
AL, alopecia; AR, arthritis; AZT, azathioprine; CPM, cyclophosphamide; FE, fever; HE, hematuria; IDB, Increased DNA binding; LC, low complement; LP, leucopenia; MMF, mycophenolate mofetil; MU, mucosal ulcers; MY, myositis; N/A, data not available; PE, pericarditis; PI, pyuria; PL, pleurisy; PRD, prednisolone; PU, proteinuria; RA, rash; SZ, seizure; TC, thrombocytopenia; UC, urinary casts; VA, vasculitis.